<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451762</url>
  </required_header>
  <id_info>
    <org_study_id>STU00044695</org_study_id>
    <nct_id>NCT01451762</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery</brief_title>
  <official_title>A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain after ambulatory surgery remains an unsolved problem in The United States and Europe. It
      is associated with delayed hospital discharge and it can result to an increased opioid
      consumption with adverse side effects. The concept of multimodal analgesic technique was
      introduced more than 15 years ago and several techniques have been studied over the years
      including non steroidal antiinflammatory drugs (NSAIDs), acetaminophen, gabapentoids,
      ketamine, local and regional anesthetic techniques. Histamine can have effects on polymodal
      nociceptors and C-fibers, producing pain which is further increased by neurogenically
      mediated release of substance P from afferent pain fibers. Several non-selective or H1
      -selective histamine receptors antagonists have been demonstrated in animal models and
      clinical pain. Chia et al demonstrated that preoperative promethazine had opioid sparing
      properties without adverse sedative effects in patients undergoing abdominal hysterectomy.

      Diphenhydramine is an anti-histamine drug who has been found to be effective in reducing
      postoperative nausea and vomiting after ambulatory surgery but its effects on postoperative
      pain and other important outcomes after ambulatory surgery such as time to meet discharge
      criteria have not being studied.

      The MQOR 40 is a validated instrument that was specifically design to evaluate patient
      recovery after anesthesia and surgery. This instrument can be particularly valid to examine
      interventions which affect different spheres of patient recovery as is the case of
      diphenhydramine. The objective of this study is to determine a dose response effect of
      preoperative diphenhydramine on postoperative quality of recovery after ambulatory surgery.
      The use of preoperative diphenhydramine can improve patient's quality of recovery, decrease
      postoperative pain, opioid consumption and opioid related side effects after ambulatory
      surgery.

      The research question: Does a preoperative dose of diphenhydramine improve postoperative
      quality of recovery after ambulatory surgery? The hypothesis of this study is that
      preoperative diphenhydramine will improve postoperative pain, Postoperative nausea and
      vomiting (PONV), sleep which will translate in a better overall quality of recovery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery 40 at 24 Hours</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>Scores on QOR (quality of recovery) 40 questionnaire.The QoR-40 score, which ranges from 40 to 200, representing very poor to outstanding quality of recovery, respectively.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Surgery</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.9 normal saline IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg diphenhydramine IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg diphenhydramine IV administered before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg diphenhydramine IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg diphenhydramine IV administered before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>.9 normal saline</intervention_name>
    <description>.9 normal saline administered before surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg diphenhydramine IV</intervention_name>
    <description>25 mg diphenhydramine IV administered before surgery</description>
    <arm_group_label>25 mg diphenhydramine IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg diphenhydramine IV</intervention_name>
    <description>50 mg diphenhydramine administered IV before surgery</description>
    <arm_group_label>50 mg diphenhydramine IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-64 years

          -  Patients undergoing ambulatory surgery

          -  ASA PS I, II.

        Exclusion Criteria:

          -  Chronic opioid use

          -  pregnant patient or lactating patients

          -  allergy to diphenhydramine

          -  glaucoma

          -  uncontrolled hypertension

          -  asthma

          -  hyperthyroidism

          -  cardiovascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens HOspital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prentice Womens HOsptial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-40, table of contents.</citation>
    <PMID>12873949</PMID>
  </reference>
  <reference>
    <citation>Benhamou D, Berti M, Brodner G, De Andres J, Draisci G, Moreno-Azcoita M, Neugebauer EA, Schwenk W, Torres LM, Viel E. Postoperative Analgesic THerapy Observational Survey (PATHOS): a practice pattern study in 7 central/southern European countries. Pain. 2008 May;136(1-2):134-41. Epub 2007 Aug 20.</citation>
    <PMID>17703887</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Dahl JB. The value of &quot;multimodal&quot; or &quot;balanced analgesia&quot; in postoperative pain treatment. Anesth Analg. 1993 Nov;77(5):1048-56. Review.</citation>
    <PMID>8105724</PMID>
  </reference>
  <reference>
    <citation>White PF, Kehlet H. Improving postoperative pain management: what are the unresolved issues? Anesthesiology. 2010 Jan;112(1):220-5. doi: 10.1097/ALN.0b013e3181c6316e. Review.</citation>
    <PMID>20010418</PMID>
  </reference>
  <reference>
    <citation>Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebj√∂rk HE. Specific C-receptors for itch in human skin. J Neurosci. 1997 Oct 15;17(20):8003-8.</citation>
    <PMID>9315918</PMID>
  </reference>
  <reference>
    <citation>Baird-Lambert J, Jamieson DD. Possible mediators of the writhing response induced by acetic acid or phenylbenzoquinone in mice. Clin Exp Pharmacol Physiol. 1983 Jan-Feb;10(1):15-20.</citation>
    <PMID>6188566</PMID>
  </reference>
  <reference>
    <citation>Rumore MM, Schlichting DA. Analgesic effects of antihistaminics. Life Sci. 1985 Feb 4;36(5):403-16. Review.</citation>
    <PMID>2578597</PMID>
  </reference>
  <reference>
    <citation>Raffa RB. Antihistamines as analgesics. J Clin Pharm Ther. 2001 Apr;26(2):81-5. Review.</citation>
    <PMID>11350529</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <results_first_submitted>October 28, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2014</results_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>anesthesia</keyword>
  <keyword>surgery</keyword>
  <keyword>postoperative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>90 subjects were enrolled between September 2011 and September 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>.9 normal saline IV</description>
        </group>
        <group group_id="P2">
          <title>25 mg Diphenhydramine IV</title>
          <description>25 mg diphenhydramine IV administered before surgery</description>
        </group>
        <group group_id="P3">
          <title>50 mg Diphenhydramine IV</title>
          <description>50 mg diphenhydramine IV administered before surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>.9 normal saline IV</description>
        </group>
        <group group_id="B2">
          <title>25 mg Diphenhydramine IV</title>
          <description>25 mg diphenhydramine IV administered before surgery</description>
        </group>
        <group group_id="B3">
          <title>50 mg Diphenhydramine IV</title>
          <description>50 mg diphenhydramine IV administered before surgery</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="8.36"/>
                    <measurement group_id="B2" value="36.5" spread="10.7"/>
                    <measurement group_id="B3" value="37" spread="8.3"/>
                    <measurement group_id="B4" value="37" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery 40 at 24 Hours</title>
        <description>Scores on QOR (quality of recovery) 40 questionnaire.The QoR-40 score, which ranges from 40 to 200, representing very poor to outstanding quality of recovery, respectively.</description>
        <time_frame>24 hours post operatively</time_frame>
        <population>Primary outcome was QOR 40 a sample size of 23 per group was estimated to achieve 80% power to detect a 10 point difference in aggregated QOR040 score for the three groups. A 10 point difference represents a clinically relevant improvement in quality of recovery. TO account for drop outs lost to follow up 90 subjects were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>.9 normal saline IV</description>
          </group>
          <group group_id="O2">
            <title>25 mg Diphenhydramine IV</title>
            <description>25 mg diphenhydramine IV administered before surgery</description>
          </group>
          <group group_id="O3">
            <title>50 mg Diphenhydramine IV</title>
            <description>50 mg diphenhydramine IV administered before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery 40 at 24 Hours</title>
          <description>Scores on QOR (quality of recovery) 40 questionnaire.The QoR-40 score, which ranges from 40 to 200, representing very poor to outstanding quality of recovery, respectively.</description>
          <population>Primary outcome was QOR 40 a sample size of 23 per group was estimated to achieve 80% power to detect a 10 point difference in aggregated QOR040 score for the three groups. A 10 point difference represents a clinically relevant improvement in quality of recovery. TO account for drop outs lost to follow up 90 subjects were randomized.</population>
          <units>units on scale 40 (low) - 200 (high)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" lower_limit="151" upper_limit="189"/>
                    <measurement group_id="O2" value="169" lower_limit="159" upper_limit="181"/>
                    <measurement group_id="O3" value="172" lower_limit="157" upper_limit="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>.9 normal saline IV</description>
        </group>
        <group group_id="E2">
          <title>25 mg Diphenhydramine IV</title>
          <description>25 mg diphenhydramine IV administered before surgery</description>
        </group>
        <group group_id="E3">
          <title>50 mg Diphenhydramine IV</title>
          <description>50 mg diphenhydramine IV administered before surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not obtain preoperative quality of recovery scores of patients therefore we could not examine whether the effect of diphenhydramine was dependent upon patient's baseline characteristics.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-472-3573</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

